Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guanxinning Tablet for angina after PCI
ChiCTR2200055524Phase 4Recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Jan 2022
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Guanxinning in angina pectoris and coronary arteriosclerosis (2 arms), sponsored by Sir Run-Run Shaw Hospital. Primary endpoint: Peak oxygen uptake. Started Jan 2022; status: recruiting.
02
Drugs
Guanxinning
03
Conditions
angina pectoriscoronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR2200055524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200055524.